Sfoglia per AUTORE
PARISI A
Collezione ASL Torino 4

  

Items : 6

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. in Nature medicine / Nat Med. 2023 Mar;29(3):605-614. doi: 10.1038/s41591-023-02240-8. Epub 2023 Mar 2.

2023
ASL Torino 4

Petrillo A; Gobba SM; Graham J; Longarini R; Garrone O; Zanaletti N; De Tursi M; Parisi A; Libertini M; Morelli C; Cergnul M; Depetris I; Ratti M; Fenocchio E; Zoratto F; Thomas A; Iveson T; Messina C; Pavarana M; Ross P; Rodriquenz MG; Stavraka C; Rosati G; Antonuzzo L; Mazzuca F; Merz V; Gelsomino F; Berardi R; Giampieri R; et alii...

Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study. in Cancers / Cancers (Basel). 2022 Nov 9;14(22):5513. doi: 10.3390/cancers14225513.

2022
ASL Torino 4
AOU Città della Salute di Torino

Parisi A; Ghidini M; Ramai D; Garrone O; Germini A; de Angelis N; Memeo R; Facciorusso A; Gjoni E; Roberto M; De Tursi M; Berardi R; Morelli C; Gelsomino F; Giampieri R; Depetris I; Zurlo IV; Nigro O; Filippi R; Salvatore L; Bonomi A; Cotsoglou C; Granieri S;

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15.

2022
AOU Città della Salute di Torino
ASL Città di Torino
ASL Torino 4

Parisi A; Ficorella C; Ferri C; Pensieri MV; Cortellini A; Aimar G; Roberto M; Petrillo A; Zoratto F; Garajova I; Spinelli GP; Vitale P; Zanaletti N; Di Pietro FR; Morelli C; De Tursi M; Giampieri R; Depetris I; Keränen SR; Ghidini M; Nigro O; Gelsomino F; Dell'Aquila E; Lombardi P; Zurlo IV; Filippi R; Porzio G; Salvatore L; Fargnoli MC; et alii...

Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis. in Frontiers in oncology / Front Oncol. 2022 Aug 12;12:935826. doi: 10.3389/fonc.2022.935826. eCollection 2022.

2022
ASL Torino 4
ASL Città di Torino
AOU Città della Salute di Torino

Ghidini M; Berardi R; Ferri C; Galassi B; Garrone O; Ciardiello D; Pensieri MV; Depetris I; Zoratto F; Di Pietro FR; Dell'Aquila E; Tomao S; Vitale P; Zurlo IV; Giordano G; Landriscina M; Petrillo A; Daniele B; De Tursi M; Di Marino P; Satolli MA; Strippoli A; Filippi R; Maratta MG; Felicetti C; Bensi M; Salvatore L; Giampieri R; Mammarella A; et alii...

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. in Clinical colorectal cancer / Clin Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. Epub 2021 Jul 18.

2021
ASL Torino 4
AOU Città della Salute di Torino

Ficorella C; D'Orazio C; Cortellini A; Petrillo A; Ierino D; Roberto M; Spinelli GP; Zoratto F; Garajova I; Ghidini M; Vitale P; Troiani T; Zanaletti N; De Galitiis F; Di Pietro FR; Tinari N; De Tursi M; Morelli C; Keränen SR; Giampieri R; Depetris I; Aimar G; Lombardi P; Claudia F; Dell'Aquila E; Spallanzani A; Leo S; Zurlo V; Gelsomino F; et alii...

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. in Frontiers in oncology / Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021.

2021
ASL Torino 4
AOU Città della Salute di Torino

Ferri C; Ficorella C; D'Orazio C; Aimar G; Patruno L; Roberto M; Petrillo A; Zoratto F; Garajova I; Spinelli GP; Zanaletti N; Vitale P; Di Marino P; Di Pietro FR; Morelli C; Giampieri R; Lombardi P; Roselló Keränen S; Depetris I; Fulgenzi C; Zurlo IV; Nigro O; Gelsomino F; Ghidini M; Tortora G; Salvatore L; Filippi R; Parisi A; Cortellini A; et alii...